Current Headlines

  1. Merck Acquires OncoEthix, Cancer Drug Lead

    Merck announced that it has acquired Swiss-based oncology firm OncoEthix through a subsidiary. The acquisition gives Merck access to an investigational drug in development for the treatment of blood malignancies and late-stage solid tumors.

  2. GSK’s Phase 3 Study For Shingles Vaccine Hits Endpoint

    GlaxoSmithKline announced positive results from its pivotal Phase 3 study investigating its vaccine HZ/su for the prevention of shingles.

  3. TxCell Wins EU Orphan Designation For Col-Treg In Uveitis

    Biotech firm TxCell announced that it has received orphan drug designation from the European Commission for its investigational immunotherapy Col-Treg intended for eye disease autoimmune uveitis.

  4. Alcon’s Xtoro For “Swimmer’s Ear” Gets FDA Green Light

    Novartis company, Alcon Laboratories, has received approval from the U.S. Food and Drug Administration (FDA) for its drug Xtoro (finafloxacin otic suspension) as treatment for acute otitis externa, also known as “swimmer’s ear.”

  5. FDA Reviews Apotex’s Biosimilar To Amgen’s Neulasta

    Apotex, a large Canadian pharmaceutical company, announced in a press release that the Food and Drug Administration (FDA) is reviewing its biosimilar in comparison to Amgen’s Neulasta.

  6. Biothera Joins Cancer Research UK Combinations Alliance

    Biothera, a U.S. company focused on cancer therapies, has joined the Combinations Alliance, a joint effort between the Cancer Research UK's Centre for Drug Development and the Experimental Cancer Medicine Centre (ECMC) Network.

  7. Curie-Cancer, GamaMabs Renew Collaboration For Biologic Ovarian Cancer Drug

    GamaMabs Pharma, a biotech specializing in the development of biologic cancer drugs, announced the extension of their collaboration with Curie-Cancer, a leading academic research institute.

  8. Zafgen Starts Phase 2 Trial Of Beloranib In Severe Obesity

    Zafgen, a company focusing on obesity and complex metabolic disorders, has begun a Phase 2 trial of beloranib.

  9. CMC Biologics, OncoSynergy To Co-Develop Ebola Drug Lead

    CMC Biologics announced that it has entered into agreement with OncoSynergy for accelerated process development and Good Manufacturing Practices (GMP) production for the investigational drug OS2966 targeting the Ebola virus.

  10. AstraZeneca Posts Positive Data For Faslodex In Breast Cancer

    AstraZeneca presented new data for its investigational drug Faslodex (fulvestrant) as treatment for hormone-receptor positive breast cancer compared to Arimidex (anastrozole) at the recent 2014 San Antonio Breast Cancer Symposium (SABCS).

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.